Analytical Data
-
Gene name
OCTN2
- Application
-
Alternative Names
SLC22A5; CDSP; SCD; Solute Carrier Family 22 Member 5; High-affinity sodium-dependent carnitine cotransporter
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Z0E8
-
Expression Region
Met1~Pro278
-
Molecular Weight
62kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OCTN2 (Nominally known as SLC22A4) is a crucial member of the organic cation/carnitine transporter family, predominantly expressed in the kidney and small intestine, where it plays a vital role in the reabsorption and transport of carnitine, an essential factor for fatty acid metabolism and energy production. Defects in OCTN2 are linked to primary systemic carnitine deficiency (PSCD), a disorder that results in impaired fatty acid oxidation, leading to debilitating symptoms and metabolic crises. Given the transporter’s significant role in carnitine homeostasis, research has focused on the structural and functional characteristics of OCTN2, particularly regarding its mechanisms of substrate transport and regulation. Recombinant OCTN2 protein is leveraged in studies to elucidate these processes, allowing for the investigation of its transport kinetics, substrate specificity, and interactions with various molecules, such as pharmaceuticals and environmental toxins. Advances in this field promise to enhance our understanding of carnitine metabolism and may inform therapeutic strategies for conditions arising from OCTN2 dysfunction, thereby addressing PSCD and other metabolic disorders linked to impaired carnitine transport. The development of OCTN2 as a recombinant protein also opens avenues for drug screening and the potential design of targeted therapies aimed at mitigating the effects of transportation deficiencies.
